Kymab Receives $40 Million Investment From Gates Foundation and Wellcome Trust - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Kymab Receives $40 Million Investment From Gates Foundation and Wellcome Trust



Kymab, a monoclonal antibody biopharmaceutical company, has raised $40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing $20 million.

The funds will enable Kymab to increase the potential of its kymouse platform and advance its pipeline of therapeutic human monoclonal antibodies in areas of unmet medical need. Kymab will also collaborate with the Gates Foundation and its partners on vaccine antigen discovery R&D with a focus on malaria and HIV. Recent data published in Nature Biotechnology demonstrates that the kymouse technology yields an antibody library constituted from 100 trillion different antibodies, in which rare high-quality antibodies can be selected and developed into therapeutics.

In addition, Kymab will pursue a limited number of collaborations to identify and develop therapeutic antibodies in a range of diseases. Kymab has also developed Kymab Access, a program that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics and vaccines by partnering with Kymab and its kymouse antibody technology.

Source: Kymab

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here